Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Account Payables: 2022-2025

Historic Change in Account Payables for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $3.3 million.

  • Centessa Pharmaceuticals' Change in Account Payables rose 92.26% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 136.34%. This contributed to the annual value of -$4.6 million for FY2024, which is 68.44% down from last year.
  • Centessa Pharmaceuticals' Change in Account Payables amounted to $3.3 million in Q3 2025, which was up 1,753.11% from $177,000 recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Change in Account Payables registered a high of $3.3 million during Q3 2025, and its lowest value of -$4.2 million during Q1 2024.
  • In the last 3 years, Centessa Pharmaceuticals' Change in Account Payables had a median value of $83,000 in 2023 and averaged -$540,455.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Change in Account Payables tumbled by 185.51% in 2023, and later skyrocketed by 1,955.42% in 2024.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Change in Account Payables stood at $2.6 million in 2022, then plummeted by 77.43% to $586,000 in 2023, then plummeted by 75.60% to $143,000 in 2024, then surged by 92.26% to $3.3 million in 2025.
  • Its Change in Account Payables stands at $3.3 million for Q3 2025, versus $177,000 for Q2 2025 and -$2.1 million for Q1 2025.